Ftse Mib
34.395,62
0,06%
DAX
18.518,03
-0,44%
S&P 500
5.667,20
0,64%
NASDAQ
18.509,34
0,20%
Bitcoin
64.603,99
-0,38%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Blueprint Medicines Corporation (BPMC) Blueprint Medicines Corporation (BPMC) Notizie

BPMC

Blueprint Medicines (BPMC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC
DataOraFonteTitoloSimboloCompagnia
02/12/201818:30PR Newswire (US)Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinica...NASDAQ:BPMCBlueprint Medicines Corporation
21/11/201813:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BPMCBlueprint Medicines Corporation
15/11/201814:48Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BPMCBlueprint Medicines Corporation
15/11/201813:00PR Newswire (US)Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Suppo...NASDAQ:BPMCBlueprint Medicines Corporation
05/11/201823:05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BPMCBlueprint Medicines Corporation
30/10/201821:44Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BPMCBlueprint Medicines Corporation
30/10/201812:00PR Newswire (US)Blueprint Medicines Reports Third Quarter 2018 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
29/10/201821:01PR Newswire (US)Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Bere...NASDAQ:BPMCBlueprint Medicines Corporation
23/10/201822:01PR Newswire (US)Blueprint Medicines to Report Third Quarter 2018 Financial Results on Tuesday, October 30, 2018NASDAQ:BPMCBlueprint Medicines Corporation
06/10/201814:50PR Newswire (US)Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Ad...NASDAQ:BPMCBlueprint Medicines Corporation
01/10/201814:00PR Newswire (US)Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inh...NASDAQ:BPMCBlueprint Medicines Corporation
26/09/201814:00PR Newswire (US)Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resista...NASDAQ:BPMCBlueprint Medicines Corporation
24/09/201814:00PR Newswire (US)Blueprint Medicines Showcases Broad Portfolio of Highly Selective Investigational Kinase Medicines with Presentations at Upco...NASDAQ:BPMCBlueprint Medicines Corporation
05/09/201814:00PR Newswire (US)Blueprint Medicines to Present at 16th Annual Morgan Stanley Global Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
04/09/201820:50Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:BPMCBlueprint Medicines Corporation
01/08/201822:44Edgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:BPMCBlueprint Medicines Corporation
01/08/201822:40Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:BPMCBlueprint Medicines Corporation
01/08/201822:01PR Newswire (US)Blueprint Medicines to Present at Upcoming Investor Conferences in AugustNASDAQ:BPMCBlueprint Medicines Corporation
01/08/201813:00PR Newswire (US)Blueprint Medicines Reports Second Quarter 2018 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
25/07/201814:00PR Newswire (US)Blueprint Medicines to Report Second Quarter 2018 Financial Results on Wednesday, August 1, 2018NASDAQ:BPMCBlueprint Medicines Corporation
21/06/201814:00PR Newswire (US)Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stroma...NASDAQ:BPMCBlueprint Medicines Corporation
15/06/201814:00PR Newswire (US)Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advan...NASDAQ:BPMCBlueprint Medicines Corporation
04/06/201813:00PR Newswire (US)Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commerci...NASDAQ:BPMCBlueprint Medicines Corporation
31/05/201814:00PR Newswire (US)Blueprint Medicines to Present at Upcoming Investor Conferences in JuneNASDAQ:BPMCBlueprint Medicines Corporation
17/05/201815:00PR Newswire (US)Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of ...NASDAQ:BPMCBlueprint Medicines Corporation
02/05/201813:00PR Newswire (US)Blueprint Medicines Reports First Quarter 2018 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
27/04/201823:57Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:BPMCBlueprint Medicines Corporation
27/04/201823:56Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BPMCBlueprint Medicines Corporation
25/04/201814:00PR Newswire (US)Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018NASDAQ:BPMCBlueprint Medicines Corporation
15/04/201815:35PR Newswire (US)Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Sele...NASDAQ:BPMCBlueprint Medicines Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC

La tua Cronologia

LSE
0MWL
Vaneck Vectors Ucits Etfs
NYSE
BML-G
Bank of America
NASDAQ
GLUU
Glu Mobile
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network